To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/24 cls
Gentium S.p.A. (NASDAQ:GENT) ThinkEquity Mani Mohindru Upgrade Buy (from sell) 1% $8.68
Mohindru also raised his target to $11 from $4 after Gentium submitted responses to Day 120 questions from EMA's CHMP related to the review of defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in

Read the full 743 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE